Alvotech Switches CEO And Takes COO From Teva
Founder Wessman Will Replace Levick As CEO, While Fridriksdottir Joins Firm From January
Executive Summary
Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.
You may also be interested in...
Wave Of New Leaders Could Reshape Generics Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
In Quick Succession: Wave Of New Leaders Could Reshape Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
After Latest Adalimumab CRL, Alvotech Gets Another New Quality Chief
Six months after replacing its chief quality officer, biosimilars specialist Alvotech has again appointed a new head of quality, in the wake of the latest US FDA knockback for its AVT02 proposed adalimumab biosimilar rival to Humira.